SHOWNOTES
In this episode, the Telltales team dives deep into healthcare investing with a focus on Vertex Pharmaceuticals and Lantheus Holdings. They also discuss Apple's AI challenges, the complexities of secure government communication, and the outlook for energy markets in light of geopolitical uncertainties and the hunt for federal spending cuts.
[00:00:00] Intro Mike welcomes listeners to the Telltales podcast, where the hosts bring the weekly Cash Flow Memo to dive deep into energy, technology, and healthcare investing.
[00:00:38] Exhibit C: World Oil supply and demand (Page 1) Hunt discusses the uncertainty around Russian sanctions and Iran's oil production, noting that the oversupply of oil is not likely to be reduced by sanctions alone.
[00:01:44] Exhibit B: US GAS DEMAND / SUPPLY (Page 1) Hunt highlights the increase in LNG demand by 1.5-2 Bcf/d, driven by faster-than-expected capacity ramp-ups at Venture Global's Plaquemines Parish and Cheniere's Corpus Christi projects. Gas prices for 2025 and 2026 are projected at $4.40.
[00:02:47] Exhibit A: US GOV'T REVENUES AND EXPENSES (Page 1) The team discusses the challenges of finding $500 billion in spending cuts as the House moves to increase the debt ceiling. Actual work on reducing spending from $6-7 trillion will likely be delayed until the 12 expenditure bills are addressed.
[00:03:45] Apple's AI Struggles (Page 1) Jason and Mike analyze Apple's challenges in developing a generative AI version of Siri, with a potential release not expected until 2027. They discuss the company's leadership changes, software issues, and the complexities of creating a secure, AI-powered virtual assistant.
[00:10:10] Security, Signal App, and Government Communication The hosts explore the challenges of secure communication for government officials, discussing the limitations of traditional secure facilities (SCIFs) and the adoption of apps like Signal. They also touch on the trade-offs between transparency and the quality of decision-making in large organizations.
[00:18:54] Healthcare Updates Hunt introduces a discussion on healthcare investing, focusing on Lantheus and Vertex Pharmaceuticals as quality businesses with strong cash flows, despite potential risks from reduced Medicare and Medicaid spending.
[00:20:12] Company Analysis: Vertex Pharmaceuticals Mike dives into Vertex Pharmaceuticals, discussing the company's unique history, its successful pivot to cystic fibrosis treatments, and its promising pipeline in non-opioid pain management. He emphasizes the importance of investing in companies with strong capital allocation and long-term growth potential.
[00:25:45] Company Analysis: Lantheus Holdings Jason explains Lantheus Holdings' business in radio diagnostics for prostate cancer imaging. While current growth has stalled due to market saturation, he highlights the potential for increased demand driven by new radiopharmaceutical treatments and the company's optionality in Alzheimer's diagnostics.
[00:28:57] Vertex Pharmaceuticals Diabetes Moonshot Discussion The team discusses Vertex's early-stage but promising type 1 diabetes treatment, which has been accelerated from phase 1 to phase 3 trials. They emphasize the importance of investing in companies with strong core businesses and considering pipeline programs as optionality.
The Telltales team covers a wide range of topics, providing valuable insights into healthcare, technology, and energy investing. Tune in next week for more in-depth discussions, starting with a deeper dive into healthcare companies like Vertex, Lantheus, and Harrow.
VRTX 0.00%↑ LNTH 0.00%↑ AAPL 0.00%↑ GOOG 0.00%↑
This podcast and the information herein are intended for informational purposes only. The views expressed herein are the author’s alone and do not constitute an offer to sell, or a recommendation to purchase, or a solicitation of an offer to buy, any security, nor a recommendation for any investment product or service. While certain information contained herein has been obtained from sources believed to be reliable, neither the author nor any of his employers or their affiliates have independently verified this information, and its accuracy and completeness cannot be guaranteed. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, timeliness or completeness of this information. The author and all employers and their affiliated persons assume no liability for this information and no obligation to update the information or analysis contained herein in the future.
This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit telltales.substack.com
